Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy

Yang, Xianzhu; Dou, Shuang; Sun, Tianmeng; Mao, Chengqiong; Wang, Hongxia; Wang, Jun

doi:10.1016/j.jconrel.2011.07.035

Cited by 220 publications

(163 citation statements)

References 51 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…Yang et al [558] Other studies introduced a plasmid that contains an siRNA sequence, targeting the MethylCpG binding domain protein 1 (MBD1), into non-cytotoxic PLGA-Poloxamer nanoparticles [559]. MBD1 is a transcriptional repressor that mediates chromatin replication and has been found overexpressed in human pancreatic carcinomas and colorectal cancer [560].…”

Section: C) Polymeric Nanoparticles In Cancer Gene Therapymentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,317

715

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: C) Polymeric Nanoparticles In Cancer Gene Therapymentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,317

715

View full text Add to dashboard Cite

show abstract

“…siRNAs are powerful tools for decreasing specific gene expression and are used in many types of cell therapy, such as cancer therapy. 48 The success of cartilage regenerative medicine is based on the phenotypic status of HACs and one of the essential components of cartilage: type II collagen. Under our experimental conditions, the expression of the two essential cartilage markers (type II collagen and aggrecan) increased in a very significant manner and was associated with an improvement in the chondrocyte phenotype index.…”

Section: Discussionmentioning

confidence: 99%

BMP-2, Hypoxia, and COL1A1/HtrA1 siRNAs Favor Neo-Cartilage Hyaline Matrix Formation in Chondrocytes

Ollitrault

Legendre

Drougard

et al. 2015

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

Osteoarthritis (OA) is an irreversible pathology that causes a decrease in articular cartilage thickness, leading finally to the complete degradation of the affected joint. The low spontaneous repair capacity of cartilage prevents any restoration of the joint surface, making OA a major public health issue. Here, we developed an innovative combination of treatment conditions to improve the human chondrocyte phenotype before autologous chondrocyte implantation. First, we seeded human dedifferentiated chondrocytes into a collagen sponge as a scaffold, cultured them in hypoxia in the presence of a bone morphogenetic protein (BMP), BMP-2, and transfected them with small interfering RNAs targeting two markers overexpressed in OA dedifferentiated chondrocytes, that is, type I collagen and/or HtrA1 serine protease. This strategy significantly decreased mRNA and protein expression of type I collagen and HtrA1, and led to an improvement in the chondrocyte phenotype index of differentiation. The effectiveness of our in vitro culture process was also demonstrated in the nude mouse model in vivo after subcutaneous implantation. We, thus, provide here a new protocol able to favor human hyaline chondrocyte phenotype in primarily dedifferentiated cells, both in vitro and in vivo. Our study also offers an innovative strategy for chondrocyte redifferentiation and opens new opportunities for developing therapeutic targets.

show abstract

“…Among nanoparticulate carriers available, polymeric nanoparticles (PN) composed of an amphipathic diblock copolymer would be one of suitable drug carriers for PS. 21,22) PN possess hydrophilic outer shell associated with an aqueous layer that protects the interaction of PN with plasma proteins such as opsonins enhancing phagocytosis by macrophages in the liver and spleen. Avoidance of removal by the reticuloendothelial system would lead to prolonged circulation in blood, a property that is essential for efficient EPR effect-driven tumor delivery of PN.…”

Section: Nano-dds Formulations For Ps and Their Delivery Into Tumor Tmentioning

confidence: 99%

Nanoparticle-Based Photodynamic Therapy: Current Status and Future Application to Improve Outcomes of Cancer Treatment

Ogawara

Higaki

2017

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an emerging cancer treatment that uses photosensitizers (PS), along with light to activate them, resulting in oxidation of various biological components in cancer tissues. However, since most potential PS are solubilized and given as aqueous solution, PS is non-specifically distributed in the body, leading to the induction of various side effects in normal tissues that are exposed to daylight such as skin and eyes. To overcome the problem associated with non-specific in vivo disposition of PS, various approaches have been applied to develop safer dosage forms for PS with more efficient tumor delivery and lower disposition to normal tissues. Passive drug targeting to tumors with nanoparticulate formulations has been recognized as one of the potentially useful approaches to improve the poor tissue specificity of conventional cancer chemotherapy and this approach should also be applicable for more efficient tumor delivery of PS. In this review article, several issues concerning the efficacy of PDT using nanoparticle-based formulations are discussed and our recent attempts to temporally enhance the vascular permeability within tumors with photodynamic treatment for the better therapeutic outcome of nanoparticle-based therapy are introduced.

show abstract

Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy

Cited by 220 publications

References 51 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

BMP-2, Hypoxia, and COL1A1/HtrA1 siRNAs Favor Neo-Cartilage Hyaline Matrix Formation in Chondrocytes

Nanoparticle-Based Photodynamic Therapy: Current Status and Future Application to Improve Outcomes of Cancer Treatment

Contact Info

Product

Resources

About